Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | HRAS |
Variant | G12X |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | HRAS G12X indicates any HRAS missense mutation that results in replacement of the glycine (G) at amino acid 12 by a different amino acid. HRAS G12 mutations are hotspot mutations that often result in decreased Hras GTPase activity, leading to activation of downstream signaling and transformation of cultured cells (PMID: 6092966, PMID: 24224811, PMID: 26985062). |
Associated Drug Resistance | |
Category Variants Paths |
HRAS mutant HRAS G12X |
Transcript | NM_005343.4 |
gDNA | chr11:g.534287_534289 |
cDNA | c.34_36 |
Protein | p.G12 |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_176795 | chr11:g.534287_534289 | c.34_36 | p.G12 | RefSeq | GRCh38/hg38 |
NM_005343.3 | chr11:g.534287_534289 | c.34_36 | p.G12 | RefSeq | GRCh38/hg38 |
NM_176795.5 | chr11:g.534287_534289 | c.34_36 | p.G12 | RefSeq | GRCh38/hg38 |
NM_001130442 | chr11:g.534287_534289 | c.34_36 | p.G12 | RefSeq | GRCh38/hg38 |
NM_001130442.2 | chr11:g.534287_534289 | c.34_36 | p.G12 | RefSeq | GRCh38/hg38 |
NM_001130442.3 | chr11:g.534287_534289 | c.34_36 | p.G12 | RefSeq | GRCh38/hg38 |
NM_005343.4 | chr11:g.534287_534289 | c.34_36 | p.G12 | RefSeq | GRCh38/hg38 |
NM_176795.4 | chr11:g.534287_534289 | c.34_36 | p.G12 | RefSeq | GRCh38/hg38 |
NM_005343 | chr11:g.534287_534289 | c.34_36 | p.G12 | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05379985 | Phase I | RMC-6236 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | Recruiting | USA | 0 |
NCT06625320 | Phase III | Fluorouracil + Leucovorin + Liposomal irinotecan Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Gemcitabine + Nab-paclitaxel RMC-6236 | Phase 3 Study of RMC-6236 in Patients with Previously Treated Metastatic Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 302) | Recruiting | USA | 1 |